← Back to Press PAGE

Explicyte – Cure51: Defying Cancer

Cure51

Publication Date:

Jul 21, 2025

"Based at the Bergonié Institute, where it has access to a technology platform that is unique in Europe, Explicyte has been chosen by biotech company Cure51 to participate in the world's largest study aimed at analyzing the biological mechanisms of exceptional cancer survivors. The goal is to develop new treatments."

Read more

NEWS

THEY SPREAD THE WORD

Go to Press page

Cancer Super-Survivors May Hold Keys to New Treatments

Researchers typically ask why people get cancer. What if they studied why some survive — or never develop the disease?

Cancer Super-Survivors May Hold Keys to New Treatments

Researchers typically ask why people get cancer. What if they studied why some survive — or never develop the disease?

Cancer Super-Survivors May Hold Keys to New Treatments

Researchers typically ask why people get cancer. What if they studied why some survive — or never develop the disease?

The Role of Real-World Evidence in Accelerating Drug Development

Nicolas Wolikow, Co-Founder and CEO at Cure51, on Ethical Principles in TechBio.

The Role of Real-World Evidence in Accelerating Drug Development

Nicolas Wolikow, Co-Founder and CEO at Cure51, on Ethical Principles in TechBio.

The Role of Real-World Evidence in Accelerating Drug Development

Nicolas Wolikow, Co-Founder and CEO at Cure51, on Ethical Principles in TechBio.

Defeating cancer: By identifying the biological mechanisms shared by tens of thousands of survivors of the most aggressive forms of cancer.

Aug 16, 2025

Join us to eradicate Cancer.

ROSALIND

Explicyte – Cure51: Defying Cancer

Publication Date:

Jul 21, 2025

Table of Contents

THEY SPREAD THE WORD

Cancer Super-Survivors May Hold Keys to New Treatments

Researchers typically ask why people get cancer. What if they studied why some survive — or never develop the disease?

Cancer Super-Survivors May Hold Keys to New Treatments

Researchers typically ask why people get cancer. What if they studied why some survive — or never develop the disease?

Cancer Super-Survivors May Hold Keys to New Treatments

Researchers typically ask why people get cancer. What if they studied why some survive — or never develop the disease?

The Role of Real-World Evidence in Accelerating Drug Development

Nicolas Wolikow, Co-Founder and CEO at Cure51, on Ethical Principles in TechBio.

The Role of Real-World Evidence in Accelerating Drug Development

Nicolas Wolikow, Co-Founder and CEO at Cure51, on Ethical Principles in TechBio.

The Role of Real-World Evidence in Accelerating Drug Development

Nicolas Wolikow, Co-Founder and CEO at Cure51, on Ethical Principles in TechBio.

Defeating cancer: By identifying the biological mechanisms shared by tens of thousands of survivors of the most aggressive forms of cancer.

Aug 16, 2025